Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Halperin

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
The American Journal of Cardiology|August 15, 1995
Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) InvestigatorsG C Flaker, K A Fletcher, R M Rothbart, et al.
The American Journal of Medicine|April 1, 1985
Femoral pseudoaneurysm following nonpenetrating trauma in a patient with aortic insufficiencyA Squire, C M Miller, S F Horowitz, et al.
American Heart Journal|May 1, 1981
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapyD P Faxon, J L Halperin, M A Creager, et al.
Journal of the American College of Cardiology|June 17, 1998
Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III InvestigatorsM Zabalgoitia, J L Halperin, L A Pearce, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2015
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2)G Y H Lip, J L Halperin, P Petersen, et al.
Journal of the American College of Cardiology|September 1, 1992
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation InvestigatorsG C Flaker, J L Blackshear, R McBride, et al.
International Journal of Cardiology|January 1, 1982
The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery diseaseD P Faxon, M A Creager, J L Halperin, et al.
Circulation|May 1, 1980
Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failureD P Faxon, M A Creager, J L Halperin, et al.
British Journal of Clinical Pharmacology|May 1, 1986
Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgeryJ L Halperin, B P Mindich, E B Rothlauf, et al.
Archives of Neurology|March 14, 2000
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypothesesR G Hart, J L Halperin, R McBride, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
The American Journal of Cardiology|August 15, 1995
Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) InvestigatorsG C Flaker, K A Fletcher, R M Rothbart, et al.
The American Journal of Medicine|April 1, 1985
Femoral pseudoaneurysm following nonpenetrating trauma in a patient with aortic insufficiencyA Squire, C M Miller, S F Horowitz, et al.
American Heart Journal|May 1, 1981
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapyD P Faxon, J L Halperin, M A Creager, et al.
Journal of the American College of Cardiology|June 17, 1998
Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III InvestigatorsM Zabalgoitia, J L Halperin, L A Pearce, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2015
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2)G Y H Lip, J L Halperin, P Petersen, et al.
Journal of the American College of Cardiology|September 1, 1992
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation InvestigatorsG C Flaker, J L Blackshear, R McBride, et al.
International Journal of Cardiology|January 1, 1982
The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery diseaseD P Faxon, M A Creager, J L Halperin, et al.
Circulation|May 1, 1980
Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failureD P Faxon, M A Creager, J L Halperin, et al.
British Journal of Clinical Pharmacology|May 1, 1986
Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgeryJ L Halperin, B P Mindich, E B Rothlauf, et al.
Archives of Neurology|March 14, 2000
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypothesesR G Hart, J L Halperin, R McBride, et al.
Pageof 8